|Articles|May 10, 2011

BioPharm Systems Joins Oracle Accelerate Program

BioPharm Systemsannounced that ASCEND has been approved as an Oracle Accelerate Solution. ASCEND is a pre-configured and enhanced version of Oracle's Siebel Clinical Trial Management System, a CRM-based solution for the centralized management of global clinical trials, designed to make this system affordable for organizations of all sizes. BioPharm Systems’ clinical trial management system (CTMS) accelerator reduces implementation costs and timeframes, and includes robust capabilities. The system can be implemented on-premises or hosted and managed by BioPharm Systems.

ASCEND has been on the market for less than two years and has been implemented at numerous global biopharmaceutical and clinical research organizations. In addition, ASCEND is also available on a software-as-a-service (SaaS) platform.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

October 14th, 2026

ACT Brief: Design Drivers of Trial Representation, eSource-to-EDC Data Automation, and Roche's ALK7 Obesity License

In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.

October 13th, 2026

IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems

The partnership gives RealTime's network of more than 3,000 research sites access to the Archer platform for direct, automated data transfer from eSource to any sponsor electronic data capture system or data destination.

October 13th, 2026

The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, identify three persistent obstacles to consistent real-world evidence generation in oncology—inconsistent data capture, structural data limitations that modeling alone can't fix, and the need for earned generalizability through deliberate multi-site validation.

A case study of how an emerging biotech moved from targeted monitoring to full clinical operations and site management across multiple studies. Credit: Stock.Adobe.com/PHOTO4U

October 12th, 2026

Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight

How a phased CRO partnership built on ICH E6(R2) and E6(R3) principles supported a multi-indication biotech portfolio.

Representation gaps in clinical trials are built into protocol, eligibility, and site decisions, not just recruitment efforts. Credit: Stock.Adobe.com/KHAN VECTOR CO.

October 12th, 2026

Beyond Outreach: Structural Drivers of Representation in Clinical Trials

The second of a two-part perspective examining why clinical trial enrollment and representation outcomes are shaped long before the first patient is screened.

October 12th, 2026

What a Practical Roadmap for FDA and EMA Quality Frameworks Actually Looks Like

In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, describe what operationalizing regulatory-grade quality frameworks requires—and why fit-for-purpose evidence generation is a transparency and documentation discipline, not just a data cleanliness exercise.

Manual protocol translation slows study budgets. AI-enabled automation can shorten the path to negotiations while shifting budget builders to review. Credit: Stock.Adobe.com/7IMJAGO

October 9th, 2026

Start Study Budgets Sooner With AI-Enabled Protocol Translation

AI can turn complex protocols into first-pass budget inputs, letting sponsors start budgeting sooner while budget builders shift from data entry to review.

October 9th, 2026

AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?

Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.

BioPharm Systems Joins Oracle Accelerate Program

Related to this article

Trending on Applied Clinical Trials Online

IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems

The Biggest Remaining Barriers to High-Quality RWE Across Oncology Data Platforms

Beyond Outreach: Structural Drivers of Representation in Clinical Trials

Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight

Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development